Researchers confirm the need for cardiac follow-up in patients with Friedreich ataxia, with particular focus on left ventricular ejection fraction (LVEF) as a predictor of worse prognosis. They ...
People living with a rare neurological degenerative disease have called on the Government to make the first treatment for the ...
Friedreich’s ataxia is an ultra-rare, inherited neurodegenerative disorder that is typically diagnosed during adolescence. Patients with Friedreich’s ataxia experience progressive loss of coordination ...
TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with ...
“In my clinical practice, I have seen the devastating impact that Friedreich’s ataxia has on patients and their families,” said Sylvia Boesch, M.D., MSc, Principal Investigator of the MOXIe study and ...
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage ...
Skyclarys activates the Nrf2 pathway which is involved in the cellular response to oxidative stress. The Food and Drug Administration (FDA) has approved Skyclarys ™ (omaveloxolone) for the treatment ...
Please provide your email address to receive an email when new articles are posted on . Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years ...
Friedreich ataxia (FA) is a rare, hereditary neurodegenerative disease that causes difficulties with coordination and balance and reduces lifespan. The disease affects approximately 1 in 50,000 people ...
AJMC ®: What is your experience in treating patients with Friedreich ataxia (FA)? PERLMAN: I’m an adult neurologist with over 30 years of experience in an academic medical setting, primarily focusing ...
Repligen Corporation, a leading supplier of critical biologic products used to manufacture biologic drugs has enrolled its first patient in a phase I clinical trial of RG2833 in adult patients with ...
PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results